慢性手湿疹单疗法的比较有效性:一个网络元分析研究
Aditya K Gupta1,2, Mary A Bamimore1, Mesbah Talukder3
1Mediprobe Research Inc., London, Ontario, Canada.
Journal of cosmetic dermatology
|November 24, 2025
概括
网络元分析比较了慢性手湿疹 (CHE) 的新疗法. 阿利特雷蒂诺因和德尔戈替尼是评估其改善手湿疹严重性指数得分的疗法之一.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
- 基于证据的医学 基于证据的医学
背景情况:
- 慢性手湿疹 (CHE) 是一种常见的职业危险,具有重大个人和职业影响.
- CHE与亚托皮性皮肤炎 (AD) 不同,并提出了独特的治疗挑战.
- 现有的文献缺乏对较新的CHE治疗方法的比较疗效数据.
研究的目的:
- 进行网络元分析 (NMA),比较慢性手湿疹 (CHE) 的新疗法的相对疗效.
- 为CHE管理中的临床决策提供基于证据的指导.
主要方法:
- 对PubMed和Scopus的系统文献审查,以确定符合条件的研究.
- 包括评估单一治疗对12周或16周手湿疹严重性指数 (HECSI) 成绩的影响的研究.
- 用于敏感性分析的网络元回归,根据年龄,性别和基线疾病严重程度进行调整.
主要成果:
- 确定了五项符合条件的研究,其中有10个活跃的比较器.
- 包括的治疗方法阿利特雷蒂诺因 (口服) 和德尔戈西提尼布 (局部) 是FDA/EMA批准的CHE.
- 通过HECSI分数的平均差异来评估有效性,并使用累计排名曲线 (SUCRA) 下面表面值来排名.
结论:
- 这项研究提供了第一个发表的NMA关于可用的CHE治疗方法.
- 比较的疗效数据可以为慢性手湿疹的临床实践和治疗选择提供信息.
- 结果旨在指导医疗保健专业人员有效管理CHE.
相关概念视频
01:22Dose-Response Relationship: Potency and Efficacy
6.3K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.3K
01:23Hand hygiene
5.5K
Asepsis is the practice of preventing or breaking the chain of infection. The nurse employs aseptic techniques to prevent the spread of microorganisms and reduce the risk of diseases. Hand hygiene is the cornerstone of aseptic techniques and is classified into medical and surgical asepsis. Medical asepsis includes hand hygiene and the use of gloves. Surgical asepsis, or the sterile technique, refers to practices that render and keep objects and areas free of microorganisms.
Hand washing...
Hand washing...
5.5K
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
143
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
143